Kadmon Holdings (KDMN) PT Raised to $9 at Raymond James

Raymond James analyst Steven Seedhouse raised the price target on Kadmon Holdings (NYSE: KDMN) to $9.00 (from $7.00) while maintaining an Outperform rating.

The analyst commented, "We initiated coverage of KDMN two days ago (link) in anticipation of positive 6-month primary analysis data from the pivotal ROCKstar study of newly named belumosudil (a.k.a. KD025) in chronic graft versus host disease (cGvHD). Data were reported this morning and were positive, as expected. We are reiterating our Outperform rating and raising our PT to $9 on increased estimates in steroid-refractory cGvHD based on subgroup analysis presented today."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Petronet LNG Ltd. (PLNG:IN) PT Raised to INR310 at ICICI Securities
• Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities